May 27, 2026 06:00PM

Mar 17, 2026 07:30AM

Mar 17, 2026 07:30AM

Feb 18, 2026 07:30AM

Dec 18, 2025 07:30AM

Oct 30, 2025 07:30AM

Aug 7, 2025 07:30AM Knight Therapeutics Reports Second Quarter 2025 Results

Aug 4, 2025 04:30PM

Jul 31, 2025 04:30PM

Mar 26, 2025 07:30AM

Oct 15, 2024 08:30AM

Feb 29, 2024 07:30AM

Oct 16, 2023 07:30AM

Oct 10, 2023 04:45PM Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil

Oct 6, 2022 06:12PM

Aug 11, 2022 07:30AM

Mar 29, 2022 07:36AM

Mar 24, 2022 07:30AM

Nov 8, 2021 10:00AM

Sep 23, 2021 07:30AM

May 14, 2021 07:30AM Thérapeutique Knight publie ses résultats du premier trimestre 2021

Mar 1, 2021 07:04PM

Sep 21, 2020 05:01PM

Sep 21, 2020 05:01PM

Aug 25, 2020 07:33AM

Aug 25, 2020 07:30AM

Aug 25, 2020 07:30AM

Apr 17, 2020 07:30AM Knight Therapeutics Announces Approval of IBSRELA™ in Canada

Nov 25, 2019 04:15PM

Jun 26, 2019 08:30AM

Jun 25, 2019 08:30AM

Jun 18, 2019 05:00PM

Apr 4, 2019 08:45AM

Mar 14, 2019 08:30PM

Jan 11, 2019 08:03AM Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada

Jan 11, 2019 08:00AM

Nov 8, 2018 06:00AM

Nov 7, 2018 04:05PM

Sep 24, 2018 04:36PM

Aug 9, 2018 09:49AM

Aug 9, 2018 06:00AM

Jul 31, 2018 04:55PM TherapeuticsMD (TXMD), Knight Therapeutics Announce Strategic Partnership

Jul 31, 2018 04:13PM

Jul 31, 2018 04:12PM

Jul 26, 2018 06:13PM

Jul 6, 2018 08:00AM

Mar 19, 2018 06:30AM

Mar 19, 2018 06:30AM

Feb 8, 2018 09:03AM 60° Pharmaceuticals (60P) Receives Priority Review Designation For Malaria Drug

Jan 4, 2018 09:45AM

322,940 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All